Cargando...
Anti-programmed cell death-1/ligand-1 (PD-1/PD-L1) antibodies for the treatment of urothelial carcinoma: state-of-the-art and future development
INTRODUCTION/BACKGROUND: Immunotherapy with programmed cell death-1/ligand-1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those w...
Gardado en:
| Publicado en: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5878995/ https://ncbi.nlm.nih.gov/pubmed/29325739 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2017.11.002 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|